ï Working on the function of CD38 and Gq protein in immune system by using CD38, Gq and Gi knockout mice. In this project we systemically studied the role of Gq protein in DC, PMN, T and B cell migration and Ca2+ signaling in response to different G protein coupled chemokine receptors, we found, Gi, Gq and CD38 all controls immune cell chemotaxis, those proteins controls different chemokine receptor functions in different cell types, and, for the first time, we found that Gi, Gq protein and CD38 controls different phases of the Ca2+ signaling in PMNs and DCs upon chemokine stimulation. We also proved that these G proteins controlled Ca2+ signaling is IP3 dependent. The Gq KO DCs have impaired migration ability toward some chemokines in vitro as well as from skin to local lymph nodes in vivo under inflammation condition.
ï Study the function of Gq protein in B cell development and function. In this study, we have found Gq knockout mice have significantly in creased marginal zone B cells and reduced follicular B cells. We also found the Gq knockout B cells have reduced Ca2+ response under BCR stimulation and reduced death rate in vitro. Further we found that 7 month old GqKO mice are serum ANA positive.
ï Another of my ongoing project is to study the role of CD38 in STZ induced diabetes. In this project we have found CD38 KO mice have significantly increased diabetes incidence after single dose STZ treatment in both Balb/c and B6 background. Immunohistochemistry stains indicated that the CD38 KO islet beta cells are more sensitive to STZ.

Developing new therapeutic strategies for cancer and autoimmune diseases with bi-affinity antibodies

ï Work on the function of TR6 and its ligand LIGHT, a member of TNF family, in immune system. This project includes 2 parts. Basic immunological study of its function and application study of TR6 transfected cancer cells as a therapeutic vaccine and TR6 transfected organ for transplantation. We found, for the first time, that the ligend of TR6, LIGHT, can reversally transduce costimulatory signals into both in mouse and human T cells. Based on our founding I designed and developed a TR6 surface expressing tumor vaccine, which could eliminate established low antigenic tumor in mouse model. And the TR6 based tumor vaccine was applied US and Canada patent.

ï Work on the therapeutic effect of LAK cell vaccine in autoimmune disease and developed a method to prepare LAK cell vaccine.
ï Research on active immunotherapy with cancer vaccine and adoptive immunotherapy with cancer vaccine activated lymphocytes in cancer animal models and cancer patients, developed a methods to prepare autologous tumor vaccine from paraffin embedded tumor tissue (granted patent in 2001)
ï Research on therapeutic vaccine for chronic HBV carriers and developed a therapeutic vaccine for that in 1997.
ï Immunology and rheumatology course teaching for medi

Clinical training in internal medicine and rheumatology

PhD in immunology

Master's degree in Pathology

Medical degree